ArticleEJHaem2020
Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect
Article in EJHaem, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.Acta haematologica · 2026Article
- Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries.Biomedicines · 2025Review
- Article
- The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research.The oncologist · 2023Article
- Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial.Oncology and therapy · 2023Article
- Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the ConnectEJHaem · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 19 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnostic and molecular genetic testing are key in advancing the treatment of acute myeloid leukemia (AML), yet little is known about testing patterns outside of clinical trials, especially in older patients. We analyzed diagnostic and molecular testing patterns over time in 565 patients aged ≥ 55 years with newly diagnosed AML enrolled in the Connect
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.